Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews · Airways

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 25%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 25%Moderate 3 · 37.5%High 1 · 12.5%

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo, on combination therapy

All‐cause mortality · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with placebo, on combination therapy (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 0.26 [0.07, 1.06]
3 studies · 492 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs ERA

All‐cause mortality · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i showed no clear difference in mortality compared with ERA (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 3.19 [0.74, 13.64]
2 studies · 272 participants
Moderate

Group 1 Pulmonary arterial hypertension ‐ PDE5i vs placebo

All‐cause mortality · pulmonary arterial hypertension

Group 1 Pulmonary arterial hypertension ‐ PDE5i leads to lower mortality compared with placebo (high certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 0.22 [0.07, 0.68]
8 studies · 1119 participants
High

Mixed Pulmonary hypertension group 2 ‐ 4 ‐ PDE5i vs placebo

All‐cause mortality · people with pulmonary hypertension group 2 ‐ 4

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Group 3 Pulmonary hypertension due to lung disease ‐ PDE5i vs placebo

All‐cause mortality · people with pulmonary hypertension due to lung disease

The review found no eligible studies for this question.

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i vs placebo

All‐cause mortality · people with pulmonary hypertension due to left‐heart disease

Group 2 Pulmonary hypertension due to left‐heart disease ‐ PDE5i showed no clear difference in mortality compared with placebo (moderate certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 1.27 [0.28, 5.8]
3 studies · 286 participants
Moderate

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Mortality ‐ sildenafil versus placebo · people with pulmonary hypertension due to CTEPH

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 20 participants
Low

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i vs placebo

Mortality ‐ sildenafil versus bosentan · people with pulmonary hypertension due to CTEPH

Group 4 Pulmonary hypertension due to CTEPH ‐ PDE5i showed no clear difference in mortality ‐ sildenafil versus bosentan compared with placebo (low certainty).

1 finding from 1 review

Phosphodiesterase 5 inhibitors for pulmonary hypertension 2019 · Cochrane Headline outcomes only
OR 1.36 [0.22, 8.48]
1 study · 106 participants
Low